Liberal Democratic Party (LDP) leader Fumio Kishida was sworn in as Japan’s 100th prime minister. While a major focus is on how he will embody his centerpiece policy proposals made during the LDP campaign, another key topic is how the…
TRENDS
Shift to Specialty - 5: Eisai, Ajinomoto Jump on Specialty Bandwagon to Seek Efficiency in GI Biz
Eisai and Ajinomoto will integrate their gastrointestinal (GI) businesses next April in an attempt to boost efficiency in sales and development activities amid a whirlwind of changes in the Japanese pharma space. The duo aim to create Japan’s largest GI…
To read the full story
Related Article
- Shift to Specialty - 4: Ceolia Pharma Aims to Be Single-Source Provider in Field of ENT
October 28, 2015
- Shift to Specialty – 3: Meiji Seika Pharma to Focus Pipeline, Optimize Sales Force
October 23, 2015
- Shift to Specialty – 2: Santen Invests in the Future Over Present Profits
October 21, 2015
- Shift to Specialty - 1: Drug Makers Urged to Retool Strategies amid Govt Pressure, Dismal Biz Environment
October 19, 2015
TRENDS
- Top 10 PHARMA JAPAN Articles in 2020
December 28, 2020
- 51 Drugs Listed in 2019 with Total Peak Sales Forecast of 370 Billion Yen, Many for Orphan Diseases
December 27, 2019
- Top 10 PHARMA JAPAN Articles in 2019
December 26, 2019
- Sales per Drug Rep Hits Record High in FY2018 as Downsizing Speeds Up
August 30, 2019
- Chugai Running Offensive/Defensive Play towards EPS Growth Goal, Hemlibra Outpaces Target
August 9, 2019
If you were able to make more money at a company you found less desirable than your current one, would it be worth it? Conversely, would you move to a better company and a better role and accept less pay?…
The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…